Evaluation the Effects of Allopurinol on Liver Enzymes, AST, ALT, and Grade of Fatty Liver on Ultrasound in Patients with Non-Alcoholic Fatty Liver Disease

Abstract

Introduction: Non-alcoholic fatty liver disease is one of the main causes of liver disease worldwide which a treatment for that is still a major challenge. The uric acid is the ultimate purine metabolism that recent studies have shown the role of that in NAFLD. Allopurinol reduces SUA by inhibiting xanthine oxidase enzyme. Purpose: Evaluating the effect of administration of Allopurinol on hepatic enzymes ALT and AST in patients with non-alcoholic fatty liver disease Methods: This study is a RCT. 100 patients were randomly selected and divided into two groups of intervention and control. The study population was aged between 18 and 65 years old with diagnosed non-alcoholic fatty liver and hyperuricemia. People who have taken drugs that affect the level of SUA, pregnant and lactating women and alcohol users have been excluded from the study. In the intervention group, 100 mg daily Allopurinol was ordered. Results: Changes in the level of liver grade and AST and ALT enzymes were not significant between two groups. Intra-group studies showed a significant decrease in the liver grade and liver enzymes versus the control group. Also, the uric acid and liver enzymes in the baseline state in control group show a strong and significant relationship with each other and at the end of the sixth month in intervention group. Conclusion: Administration of Allopurinol at a dose of 100 mg/day can not significantly decrease the level of liver grade and liver enzymes. However, in-group studies have led to a reduction in the studied variables.